BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Moody TW, Moreno P, Jensen RT. Neuropeptides as lung cancer growth factors. Peptides 2015;72:106-11. [PMID: 25836991 DOI: 10.1016/j.peptides.2015.03.018] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Moreno P, Ramos-Álvarez I, Moody TW, Jensen RT. Bombesin related peptides/receptors and their promising therapeutic roles in cancer imaging, targeting and treatment. Expert Opin Ther Targets 2016;20:1055-73. [PMID: 26981612 DOI: 10.1517/14728222.2016.1164694] [Cited by in Crossref: 50] [Cited by in F6Publishing: 47] [Article Influence: 8.3] [Reference Citation Analysis]
2 Datta S, Roy A. Antimicrobial Peptides as Potential Therapeutic Agents: A Review. Int J Pept Res Ther 2021;27:555-77. [DOI: 10.1007/s10989-020-10110-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
3 Moreno P, Mantey SA, Lee SH, Ramos-Álvarez I, Moody TW, Jensen RT. A possible new target in lung-cancer cells: The orphan receptor, bombesin receptor subtype-3. Peptides 2018;101:213-26. [PMID: 29410320 DOI: 10.1016/j.peptides.2018.01.016] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
4 Nikolaou S, Qiu S, Fiorentino F, Simillis C, Rasheed S, Tekkis P, Kontovounisios C. The role of Neurotensin and its receptors in non-gastrointestinal cancers: a review. Cell Commun Signal 2020;18:68. [PMID: 32336282 DOI: 10.1186/s12964-020-00569-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
5 Rasaeifar B, Gomez-Gutierrez P, Perez JJ. New Insights into the Stereochemical Requirements of the Bombesin BB1 Receptor Antagonists Binding. Pharmaceuticals (Basel) 2020;13:E197. [PMID: 32824403 DOI: 10.3390/ph13080197] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
6 Khan M, Huang T, Lin CY, Wu J, Fan BM, Bian ZX. Exploiting cancer's phenotypic guise against itself: targeting ectopically expressed peptide G-protein coupled receptors for lung cancer therapy. Oncotarget 2017;8:104615-37. [PMID: 29262666 DOI: 10.18632/oncotarget.18403] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
7 Yue J, Dai Q, Hao S, Zhu S, Liu X, Tang Z, Li M, Fang H, Lin C, Luo Z. Suppression of the NTS-CPS1 regulatory axis by AFF1 in lung adenocarcinoma cells. J Biol Chem 2021;296:100319. [PMID: 33493519 DOI: 10.1016/j.jbc.2021.100319] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
8 Moody TW, Ramos-Alvarez I, Jensen RT. Neuropeptide G Protein-Coupled Receptors as Oncotargets. Front Endocrinol (Lausanne) 2018;9:345. [PMID: 30008698 DOI: 10.3389/fendo.2018.00345] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
9 Béraud-Dufour S, Devader C, Massa F, Roulot M, Coppola T, Mazella J. Focal Adhesion Kinase-Dependent Role of the Soluble Form of Neurotensin Receptor-3/Sortilin in Colorectal Cancer Cell Dissociation. Int J Mol Sci 2016;17:E1860. [PMID: 27834811 DOI: 10.3390/ijms17111860] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
10 Jiang SH, Hu LP, Wang X, Li J, Zhang ZG. Neurotransmitters: emerging targets in cancer. Oncogene 2020;39:503-15. [PMID: 31527667 DOI: 10.1038/s41388-019-1006-0] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 9.3] [Reference Citation Analysis]
11 Moody TW, Tashakkori N, Mantey SA, Moreno P, Ramos-Alvarez I, Leopoldo M, Jensen RT. AM-37 and ST-36 Are Small Molecule Bombesin Receptor Antagonists. Front Endocrinol (Lausanne) 2017;8:176. [PMID: 28785244 DOI: 10.3389/fendo.2017.00176] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
12 Moody TW, Nuche-Berenguer B, Jensen RT. Vasoactive intestinal peptide/pituitary adenylate cyclase activating polypeptide, and their receptors and cancer. Curr Opin Endocrinol Diabetes Obes 2016;23:38-47. [PMID: 26702849 DOI: 10.1097/MED.0000000000000218] [Cited by in Crossref: 51] [Cited by in F6Publishing: 33] [Article Influence: 8.5] [Reference Citation Analysis]
13 Zhang YF, Zhang J, Sun CC, Tang CY, Sun GY, Luo WJ, Zhou Y, Guan CX. Vasoactive intestinal peptide inhibits the activation of murine fibroblasts and expression of interleukin 17 receptor C. Cell Biol Int 2019;43:770-80. [PMID: 31026365 DOI: 10.1002/cbin.11151] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]